The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Nodel' M.R.

Kafedra nervnykh bolezneĭ lechebnogo fakul'teta Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Ukraintseva Yu.V.

Institute of Higher Nervous Activity and Neurophysiology Russian Academy of Sciences, Moscow, Russia

Iakhno N.N.

Kafedra nervnykh bolezneĭ i otdel nevrologii i klinicheskoĭ neĭrofiziologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Syndrome of rapid eye movement sleep behavior disorder and nocturia in Parkinson’s disease

Authors:

Nodel' M.R., Ukraintseva Yu.V., Iakhno N.N.

More about the authors

Read: 3055 times


To cite this article:

Nodel' MR, Ukraintseva YuV, Iakhno NN. Syndrome of rapid eye movement sleep behavior disorder and nocturia in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):15‑20. (In Russ.)
https://doi.org/10.17116/jnevro20171179115-20

References:

  1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS Clinical Diagnostic Criteria for Parkinsons Disease. Movement Disorders. 2015;30(12):1591-1599. https://doi.org/ 10.1002/mds.26424
  2. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS Research Criteria for Prodromal Parkinsons Disease. Movement Disorders. 2015;30(12):1600-1609. https://doi.org/ 10.1002/mds.26431
  3. Soh Sze-Ee, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2011;17:1-9. https://doi.org/10.1016/j.parkreldis.2010.08.012
  4. Nodel МR. The impact of neuropsychiatric symptoms on quality of life of patients with Parkinsons disease. Neurologicheskiy zhurnal. 2015;1:20-25. (In Russ.). https://doi.org/10.18821/1560-9545-2015-20-1-20-27
  5. Arnulf I. REM sleep behavior disorder: motor manifestations and pathophysiology. Movement Disorders. 2012:27:677-689.
  6. Oudiette D, De Cock VC, Lavault S, et.al. Nonviolent elaborate behaviors may also occur in REM sleep behavior disorder. Neurology. 2009;72:551-557.
  7. Postuma RB, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y et al. A Single-Question Screen for rapid eye movement sleep behavior disorder: A Multicenter Validation Study. Movement Disorders. 2012;27(7):913-916.
  8. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Martí MJ, Valldeoriola F et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5:572-577.
  9. Postuma RB, Bertrand J-A, Montplasir J et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinsons Disease. Movement Disorders. 2012;6:720-726.
  10. Iranzo A, Valldeoriola F, Lomena F, Molinuevo JL, Serradell M, Salamero M et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011;10:797-805.
  11. Lima MM. Sleep disturbances in Parkinson’s disease: the contribution of dopamine in REM sleep regulation. Sleep Med Rev. 2012;17(5):367-375.
  12. Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: A review. Parkinsonism and Related Disorders. 2009;15(2):81-87.
  13. Nodel MR, Yakhno NN, Ukraintseva YuV, Dorochov VB. Insomnia in Parkinsons disease and their impact on patients quality of life. Neurologicheskiy zhurnal. 2014;4(19):19-27. (In Russ.).
  14. Kulua TK, Fedorova NV. Nocturnal symptoms of Parkinson’s disease and approaches to their correction. Zurnal neurologii i psikhiatrii im. S.S. Korsakova. 2013;113:12(111):62-66. (In Russ.).
  15. Fahn S, Elton RL. UPDRS Development Committee. Unified Parkinson’s disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson’s Disease. Florham Park, NJ: Macmillan; 1987.
  16. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629-635.
  17. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: A review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. Journal of Neurology. 1998;245(suppl 1):10-14.
  18. Sixel-Döring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology. 2011;77(11):1048-1054.
  19. Nodel MR, Rusakova IM, Yakhno NN. Clinic assessment of sleep and wakefulness disturbances in Parkinson’s disease. Neurologicheskiy zhurnal. 2010 2:19-25. (In Russ.).
  20. Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: A review. Parkinsonism and Related Disorders. 2009;15(2):81-87.
  21. Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T. SPECT imagimg of the dopamine transporter with 123-I-beta —CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction. J Neurol Sci. 2001;187(1-2):55-59.
  22. Winge K, Friberg L, Werdelin L, Nielson K, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. European Journal of Neurology. 2005;12:842-850.
  23. Nodel MR, Yakhno NN. Mirapex (pramipexole) in the treatment nonmotor symptoms in Parkinson’s disease. Zurnal neurologii i psikhiatrii im. S.S. Korsakova. 2008;108: 5:32-38. (In Russ.).
  24. Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical psychiatry: an update. J Psychosom Res. 2002;53:67-654.
  25. Kovalzon VМ. Biological clocks: the mechanisms of circadian rhythms. In: the basis of somnology. М.: Бином; 2011. (In Russ.).
  26. Cauter Evan, Tasali E. Endocrine Physiology in Relation to Sleep and Sleep Disturbances. In: Kryger M., Roth T., Dement W.C., eds. Principles and Practice of Sleep Medicine. 6 nd ed. Philadelphia, PA: Elsievier; 2017.
  27. Hineno T, Mizobuchi M, Hiratani K, Inami Y, Kakimoto Y. Disapperance of circadian rhythms in Parkinson’s disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs. Brain Res. 1992;580:92-99.
  28. Zhong G, Bolitho S, Grunstein R, Naismith SL, Lewis SJ. The Relationship between Thermoregulation and REM Sleep Behaviour Disorder in Parkinson’s Disease. PLoS ONE. 2013;8(8):72661.
  29. Gravotta L, Gavrila AM, Hood S, Amir S. Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. J Mol Neurosci. 2011;45:162-171.
  30. Archibald NK, Clarke MP, Mosimann UP, et al. The retina in Parkinson’s disease. Brain. 2009;132:1128-1145.
  31. Breen DP, Vuono R, Nawarathna U, et al. Sleep and Circadian Rhythm in Early Parkinson Disease. JAMA Neurol. 2014;71(5):589-595.
  32. Adi N, Mash DC, Ali E, et al. Melatonin MT1 and MT2 receptors expression in Parkinsons disease. Med Sci Monit. 2010.61-67.
  33. Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behavior disorder. J Sleep Res. 2010;19:591-596.
  34. Нодель М.Р. Современные возможности терапии нарушений сна у пациентов с болезнью Паркинсона. Неврология. Нейропсихиатрия. Психосоматика. 2013;2:30-34.
  35. Boulamery A, Simon N, Vidal J, Bruguerolle B. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol Int. 2010;27:251-264.
  36. Bolitho SJ, Naismith SL, Rajaratnam SM, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Medicine. 2014;15:342-347.
  37. Nodel MR, Ukraintseva YuV, Yakhno NN. Rapid-eye-movement sleep behaviour disorder in Parkinson’s disease. Neurologicheskiy zhurnal. 2015;6:28-34. (In Russ.).
  38. Erro R, Picillo M, Amboni M, Moccia M, Vitale C, Longo K, et al. Nonmotor predictors for levodopa requirement in de novo patients with Parkinson’s disease. Mov Disord. 2015;30(3):373-378.
  39. Tracey DJ, Paxinos G, Stone J. Neurotransmitters in the Human Brain. New York: Plenum Press; 1995.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.